drugset / Trial / NCT02242981

A Study of How the Body Breaks Down and Eliminates LY2623091

NCT02242981

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

This type of study is called a radiolabeled study. For this study, LY2623091 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element, carbon. This study will increase understanding about how the drug appears in the blood, urine, and stool after it is administered to healthy participants. Information about any side effects that may occur will also be collected. This study will last up to 22 days for each participant, not including screening. Screening is required within 28 days prior to enrollment

Timeline

Start
2014-09
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2623091 Small molecule Oral

Indications

No indication recorded.